Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

3(60%)

Results Posted

100%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph phase_1

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(1)

Terminated(1)

Detailed Status

Recruiting3

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

recruiting360%

terminated120%

completed120%

Recent Activity

3 active trials

Showing 5 of 5

recruitingphase_1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873

recruitingphase_1

PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)

NCT04582916

recruitingphase_1

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

NCT06920628

completed

Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)

NCT03324646

terminatedphase_2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

NCT05062083

Clinical Trials (5)

Showing 5 of 5 trials

NCT04396873Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Recruiting

NCT04582916Phase 1

PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)

Recruiting

NCT06920628Phase 1

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Recruiting

NCT03324646

Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)

Completed

NCT05062083Phase 2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5